PolyPid Ltd.

PYPD | NASDAQ

Price Alert Chart Builder DCF Calculator

$5.31

+$0.14 (+2.71%)

Sep 22, 2026, 12:16 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.71%

(1D)

Rating

Updated: Aug 13, 2026

23.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $101.33M

1D Range

5.25 5.31

52W Range

3.06 5.73

Valuation (TTM)

PE -3.49

PB 18.31

EV/EBITDA -3.04

Valuation (NTM)

Forward PE N/A

Forward PEG 0.13

Price Target $12.50

Cash Flow

FCF Yield 0.0%

SBC Adj. FCF Yield 0.0%

SBC Impact N/A

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 82.9% | 82.6%

FCF 3Y | 5Y 66.3% | 100.0%

Returns

ROA -206.8%

ROE -311.1%

ROIC 11.7%

Financial Health

Net Cash

$6.56M

Current Ratio 1.35

Interest Coverage 48.50

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary...

Sector Healthcare

Industry Biotechnology

Employees 72

IPO Date Jun 25, 2020

Website www.polypid.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 11, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$12.50

Upside

+135.40%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞